In addition, NSCLC with sensitive epidermal growth factor receptor (EGFR) mutations are well responded to tyrosine kinase inhibitors (TKI) and these patients will have a longer progression-free survival (PFS) than the patients whose tumors do not contain EGFR mutations [1, 10]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.